An open-label, extension study of pamrevlumab
Latest Information Update: 23 Jul 2019
Price :
$35 *
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors FibroGen
- 23 Jul 2019 New trial record